PROGRESS ON THERAPY OF BREAST-CANCER WITH VITAMIN-Q(10) AND THE REGRESSION OF METASTASES

Over 35 years, data and knowledge have internationally evolved from biochemical, biomedical and clinical research on vitamin Q(10) (coenzyme Q(10); CoQ(10)) and cancer,which led in 1993 to overt complete regression of the tumors in two cases of breast cancer. Continuing this research, three additional breast cancer patients also underwent a conventional protocol of therapy which included a daily oral dosage of 390 mg of vitamin Q,, (Bio-Quinone of Pharma Nord) during the complete trials over 3-5 years. The numerous metastases in the liver of a 44-year-old patient ''disappeared,'' and no signs of metastases were found elsewhere. A 49-year-old patient, on a dosage of 390 mg of vitamin Q(10), revealed no signs of tumor in the pleural cavity after six months, and her condition was excellent. A 75-year-old patient with carcinoma in one breast, after lumpectomy and 390 mg of CoQ(10), showed no cancer in the tumor bed or metastases. Control blood levels of CoQ(10) of 0.83-0.97 and of 0.62 mu g/ml increased to 3.34-3.64 and to 3.77 mu g/ml, respectively, on therapy with CoQ(10) for patients A-MRH and EEL. (C) 1995 Academic Press, Inc.